Allergan Submits Prior Approval Supplement For Restasis - Quick Facts

(RTTNews) - Allergan plc (AGN) said it has submitted a Prior Approval Supplement or PAS for Restasis, seeking approval of a Multi-Dose Preservative-Free or MDPF presentation.

Restasis 0.05%, or Cyclosporine Ophthalmic Emulsion, is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca, a type of Chronic Dry Eye disease.

Allergan noted that increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.

If approved, Restasis in the MDPF bottle offers patients the same formula in a multi-dose system with patented uni-directional valve and air filter technology.